|
Jan 14
|
When Will Ardelyx, Inc. (NASDAQ:ARDX) Turn A Profit?
|
|
Jan 10
|
The 3 Best Under-$10 Stocks to Buy in January 2024
|
|
Jan 8
|
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
|
|
Dec 29
|
Insider Sell: CFO Justin Renz Sells 225,000 Shares of Ardelyx Inc (ARDX)
|
|
Dec 20
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
|
Dec 18
|
There's Reason For Concern Over Ardelyx, Inc.'s (NASDAQ:ARDX) Massive 36% Price Jump
|
|
Nov 6
|
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
|
|
Nov 3
|
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
|
|
Nov 2
|
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
|
|
Oct 23
|
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
|
|
Oct 19
|
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
|
|
Oct 18
|
Why Ardelyx Stock Popped Today
|
|
Oct 18
|
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
|
|
Oct 17
|
UPDATE 2-US FDA approves Ardelyx's kidney disease-related drug
|
|
Oct 17
|
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
|
|
Oct 17
|
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
|
|
Oct 4
|
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
|
|
Jul 16
|
Loss-Making Ardelyx, Inc. (NASDAQ:ARDX) Expected To Breakeven In The Medium-Term
|
|
Jul 13
|
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
|
|
Apr 26
|
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
|